The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical impact of R0 resection after chemotherapy in initially unresectable metastatic colorectal cancer: A pooled analysis of the ARCAD database.
 
Koji Ando
Honoraria - Merck
 
Toshihiro Misumi
Honoraria - Miyarisan pharmaceutical
Consulting or Advisory Role - Anaut Inc.
 
Hideaki Bando
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Tomomi Nishikawa
No Relationships to Disclose
 
Tim Maughan
Employment - Great Western Hospital NHS Foundation trust; University of Liverpool
Consulting or Advisory Role - AstraZeneca/MedImmune; Dpertment of Oncology, University of Oxford; Ground Truth Laboratories; Nordic Bioscience; Perspectum Diagnostics
Research Funding - Almac Diagnostics (Inst); AstraZeneca (Inst); Merck KgAA (Inst); PsiOxus Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - patent pending
 
Eduardo Díaz-Rubio
No Relationships to Disclose
 
Kenichi Sugihara
No Relationships to Disclose
 
Yoshihiko Maehara
No Relationships to Disclose
 
Thierry Andre
Honoraria - Bristol-Myers Squibb; Merck; Merck Serono; Roche; Sanofi; Seagen; SERVIER
Consulting or Advisory Role - Abbvie; Aptitude Health; Aptitude Health; Biocartis; Bristol-Myers Squibb; Exelixis; Gilead Sciences; GlaxoSmithKline; Lilly; Medicenna; MSD Oncology; Nimbus Therapeutics; Nordic Bioscience; Pfizer; Roche; Sanofi; Sanofi; Seagen; SERVIER; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squib; Bristol-Myers Squibb; Merck; MSD Oncology; Takeda
Other Relationship - Inspirna
(OPTIONAL) Uncompensated Relationships - Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group; ARCAD Foundation; ARCAD Foundation
 
Qian Shi
Consulting or Advisory Role - Abbvie; Agenus; BeOne Medicines; BMS; Exelixis; Genmab US, Inc; Hoosier Cancer Research Network; HopeAI, Inc; Mirati Therapeutics; Regeneron
Research Funding - BMS (Inst); Janssen (Inst); MPAACT (Inst); Novartis (Inst); Regeneron (Inst); Roche/Genentech (Inst)
 
Aimery De Gramont
No Relationships to Disclose
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; Ono Pharmaceutical; Takeda
Consulting or Advisory Role - Indivumed; Sumitomo Corp.
Research Funding - Bristol-Myers Squibb Japan (Inst); Caris MPI (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); Exact Sciences (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Miyarisan pharmaceutical (Inst); MSD (Inst); Natera (Inst); Nippon Boehringer Ingelheim (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Eiji Oki
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Guardant Health